Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial

Frederik Ivar Persson, P Rossing, H Reinhard, T Juhl, C D A Stehouwer, C Schalkwijk, A H J Danser, F Boomsma, E Frandsen, H-H Parving

29 Citationer (Scopus)

Abstract

The optimal antiproteinuric dose of aliskiren is unknown. This study compared the effect of placebo and increasing doses of aliskiren on urinary albumin excretion rate (UAER).
OriginalsprogEngelsk
TidsskriftDiabetologia
Vol/bind53
Udgave nummer8
Sider (fra-til)1576-80
Antal sider5
ISSN0012-186X
DOI
StatusUdgivet - 1 aug. 2010

Fingeraftryk

Dyk ned i forskningsemnerne om 'Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater